Treatment Options for a Young, Fit Patient Newly Diagnosed with AML
The panel discuss the need for personalized treatment approaches for young, fit patients with newly diagnosed acute myeloid leukemia, as well as when transplant should be considered.
Implementing Real-world Evidence into Clinical Practice in NDMM
Clinical pearls for community oncologists concerning the real-world application of existing treatments while considering feasibility, cost, and ease of care.
Assessing and Supporting Frail Patients with NDMM
Conversation centered around patient frailty, Dr. Cook and Dr. Pianko emphasize the importance of accurately assessing frailty and adjusting treatment plans accordingly.
Long-Term Followup With Talquetamab in Relapsed/Refractory MM: Infection Rates
Expert hematologist-oncologists identify long-term data from MonumenTAL-1 regarding infection rates in patients with relapsed/refractory multiple myeloma.
Practical Considerations for Talquetamab Use in Relapsed/Refractory Multiple Myeloma
Following their review of data from MonumenTAL-1, Ajai Chari, MD, and Carolina Schinke, MD, share practical considerations for real-world use of talquetamab in relapsed/refractory multiple myeloma.
Pembrolizumab Plus Axitinib Versus Sunitinib for First-Line Treatment of Advanced Clear Cell RCC
Brian Rini, MD, reviews data from the 5-year analysis of the KEYNOTE-426 trial in advanced clear cell renal cell carcinoma.
Lenvatinib Plus Pembrolizumab Versus Sunitinib in Patients With Advanced Renal Cell Carcinoma (aRCC)
Robert Motzer, MD, presents the overall survival analysis data from the 4-year follow-up of the CLEAR study in patients with advanced renal cell carcinoma.
Diagnosis, Biomarker Testing, and Optimizing Treatment Selection for Patients with AML
Drs. Koprivnikar, McCloskey, and Cho delve into the diagnostic process in acute myeloid leukemia (AML), treatment approaches for AML, and factors influencing treatment selection.
Innovations in MPN Therapy: Ongoing Trials and Latest Findings
A closer look at the current unmet needs in MPN treatment, ongoing trials, and recent updates such as the MOMENTUM and FREEDOM trials.
Diagnosing Bladder Cancer: Best Practices in Workup and Staging
Shared insight on the standard work-up and staging practices used when a patient presents with newly diagnosed bladder cancer.
Patient Case Review: What is a Typical Presentation of Bladder Cancer?
Expert panelists review a patient presentation of bladder cancer and consider the typical signs and symptoms that may lead to a diagnosis.
Community Care Provider’s Perspective on Administering Bispecifics in Patients with MM
Focused discussion on how patients receiving bispecific therapy for multiple myeloma are transitioned into and managed within the community setting.
Bispecifics in Multiple Myeloma: Transitioning Patient Care to the Community Setting
Expert panelists share insight on transitioning patients on bispecific therapy from an academic or specialty center to the community setting.
The Future of Treatment for Patients with MDS
Dr. Daver anticipates how the MDS landscape will evolve over time, emphasizing the importance of adopting targeted therapies.
Targeting CD47 in MDS: Reviewing the CD47 Pathway and Key Trial Data
Subject-matter expert provides an overview of the CD47 pathway and shares how emergent trial data are impacting the MDS treatment landscape.
Discussing Bispecific Antibody Treatment With Patients With Multiple Myeloma
Catherine Wei, MD, and David Witt, MD, explain some of the reasons they would recommend treatment with bispecific antibodies to their patients with multiple myeloma.
Uncommon EGFR Mutations in Advanced Non–Small Cell Lung Cancer
Shared insight on uncommon EGFR mutations in patients with non–small cell lung cancer and how they fit into the larger disease paradigm.
Application of Bispecific Therapy in Clinical Practice
Syed S. Ali, MD, and Noffar Bar, MD, share their practical experience with bispecific antibodies in the treatment of patients with multiple myeloma.
Paradigm of NGS Testing in Patients With Advanced NSCLC
T-DXd May be ‘Practice Changing’ in HER2+ Gynecologic Cancers
Trastuzumab deruxtecan appears to elicit ‘impressive’ responses among patients with HER2-positive gynecologic cancers regardless of immunohistochemistry in the phase 2 DESTINY-PanTumor02 trial.
